METHODS FOR RAPID DISEASE SCREENING

• US 20100197510A1
• Filed: 03/07/2008
• Published: 08/05/2010
• Est. Priority Date: 03/08/2007
• Status: Abandoned Application

• Current Assignee: Rules-Based Medicine, Inc.
• Original Assignee: Rules-Based Medicine, Inc.
• Inventors: Mapes, James P., Benson, Craig, Spain, Michael, McDade, Ralph L.
• Application Number:
  US12/529,840
• Publication Number:
  US 20100197510A1
• Time in Patent Office: Days
• US Class Current: 506/7
• CPC Class Codes: G01N 33/6803 General methods of protein analysis not limited to specific proteins or families of proteins

Abstract

Methods are provided for screening for the necessity for further diagnosis of one or more diseases or conditions in a subject, which methods are based on the discovery that abnormal levels of selected analytes in a sample fluid from a subject can be correlated with specific diseases or conditions. Further provided are criteria, and methods for the determine thereof, for selected analytes with respect to selected diseases or conditions. Thus, a variety of diseases or conditions can be screened in a rapid, cost-effective composite assay. The methods are useful for screening of newborn humans for a variety of diseases and conditions, whereby additional diagnostic procedures need only be conducted for those diseases or conditions indicated by the methods of the invention.

Claims

1. A method of screening for the necessity for further diagnosis of one or more diseases or conditions in a human subject, said method comprising:

(a) obtaining a fluid sample from a human subject in need of screening for the necessity for further diagnosis of one or more diseases or conditions;

(b) determining the concentration of one or more analytes in said fluid sample;

(c) comparing each said concentration of said one or more analytes with independently selected screening criteria, wherein said independently selected screening criteria are adapted such that the sensitivity of a composite assay is at least 80%; and

(d) determining if said further diagnosis is required, thereby providing said screening for the necessity for further diagnosis of said one or more diseases or conditions in said human subject.

2. The method according to claim 1, wherein said human subject is a newborn.

3. The method according to claim 1, wherein said sensitivity is at least 90%.

4. The method according to claim 1, wherein said sensitivity is at least 95%.

5. The method according to claim 1, wherein said sensitivity is at least 99%.

6. The method according to claim 1, wherein said sensitivity is 100%.

7. The method according to claim 1, wherein said independently selected screening criteria are further adapted such that the specificity of said composite assay is at least 50%.

8. The method according to claim 1, wherein said specificity is at least 90%.

9. The method according to claim 1, wherein said specificity is at least 95%.

10. The method of claim 1, wherein said diseases or conditions are selected from the group consisting of biotimidase deficiency, congenital adrenal hyperplasia, congenital hypothryoidism, galactosemia, hemocystinuria, maple syrup urine disease, medium chain acyl-CoA dehydrogenase deficiency, phenylketonuria, sickle cell disease, tyrosinemia of type 1, fatty acid oxidation disorder, organic acid disorder, urea cycle disorder, cystic fibrosis, hemoglobin C trait and hemoglobin E trait;

wherein said fatty acid oxidation disorder is selected from the group consisting of carnitine uptake defect, long-chain hydroxyacyl-CoA dehydrogenase deficiency, trifunctional protein deficiency, and very-long-chain acyl-CoA dehydrogenase deficiency;

wherein said organic acid disorder is selected from the group consisting of 3-methylcrontonyl-CoA carboxylase deficiency, beta-ketothiolase deficiency, glutaric acidemia type I, hydroxymethylglutaric aciduria, isovaleric acidemia, form Cbl A methylmalonic acidemia, form Cbl B methylmalonic acidemia, mutase deficiency form methylmalonic acidemia, multiple carboxylase deficiency, and propionic acidemia; and

wherein said urea cycle disorder is selected from the group consisting of argininosuccinic acidemia and citrullinemia.

11. The method according to claim 1, wherein said one or more analytes are selected from the group consisting of nucleic acids, proteins, polypeptides, peptide hormones and steroid hormones.

12. The method according to claim 1, wherein said fluid sample is selected from the group consisting of blood spots, whole blood, plasma, serum, and urine.

13. The method according to claim 1, wherein said determining comprises one or more immunoassays for said one or more analytes in said fluid sample.

14. A method for selecting independent screening criteria for a composite assay, said method comprising:

(a) providing a first plurality of analyte concentrations obtained from fluid samples from a first group of subjects, said first group of subjects having no diagnosis for a first disease;

(b) providing a second plurality of analyte concentrations obtained from fluid samples from a second group of subjects, said second group of subjects having a diagnosis for said first disease;

(c) performing a principal component analysis of said first and second pluralities of said analyte concentrations, thereby providing an ordered list of principal components; and

(d) selecting one or more analytes and associated criteria for a composite assay based on relative weights of said analytes in said ordered list of principal components, thereby providing independent screening criteria for a composite assay.

15. The method according to claim 14, wherein the sensitivity of said composite assay is at least 80%.

16. The method according to claim 14, wherein the sensitivity of said composite assay is at least 90%.

17. The method according to claim 14, wherein the sensitivity of said composite assay is at least 95%.

18. The method according to claim 14, wherein the sensitivity of said composite assay is 100%.

19. The method according to claim 14, wherein the number of said selected analytes is 1.

20. The method according to claim 14, wherein the number of said selected analytes is 2-10.

21. The method according to claim 14, wherein the number of said selected analytes is 11-20.

22. The method according to claim 14, wherein the number of said selected analytes is 21-30.

23. The method according to claim 14, wherein the number of said selected analytes is greater than 30.

24. A method for selecting a plurality of analytes and associated screening criteria suitable for a composite assay useful for the determination of the necessity for further diagnosis of a plurality of diseases or conditions in a human subject, said method comprising:

(a) providing a first set of analytes and associated screening criteria adapted to evaluate the likelihood that a human subject is suffering from a first disease or condition;

(b) providing a second set of analytes and associated screening criteria adapted to evaluate the likelihood that said human subject is suffering from a second disease or condition; and

(c) selecting common analytes and associated screening criteria from said sets of analytes and associated screening criteria,

thereby providing said analytes and associated screening criteria for said composite assay.

25. The method of claim 24, wherein steps (b) and (c) are repeated with an additional set of analytes and associated screening criteria adapted to evaluate the likelihood that said human subject is suffering from another disease or condition.